Results 161 to 170 of about 205,719 (255)

Ovarian Cancer Susceptibility and Chemosensitivity to KRAS Modulation. [PDF]

Int J Mol Sci
Psaras AM, McKay SJ, Vasquez Vilela J, Ospina Sanchez E, Cintrón MG, Elder KK, Brooks TA.   +6 more
europepmc   +1 more source

Lung adenocarcinoma with KRAS-Q61H: clinicopathologic features, diagnostics, and the evolving treatment landscape. [PDF]

Front Oncol
Serafimidis I.
europepmc   +1 more source

Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report [PDF]

, 2019
Callebout, Eduard, Claes, Kathleen, De Man, Marc, Ferdinande, Liesbeth, Geboes, Karen, Laurent, Stéphanie, Moura Ribeiro, Suzane, Van der Meulen, Joni   +7 more
core   +2 more sources

Design, synthesis and biological evaluation of novel KRAS-G12D inhibitors. [PDF]

J Enzyme Inhib Med Chem
Baig MH, Jo YS, Nale SD, Kim CJ, Park J, Ha J, Moon B, Ryu S, Dong JJ.   +8 more
europepmc   +1 more source

Discovery of a novel <i>ITPR2::KRAS</i> fusion in large cell neuroendocrine lung cancer: a case report. [PDF]

Transl Lung Cancer Res
Patregnani AJ, Rouf R, Moline DR, von Dohlen G, Makovec A, Mroz P, Nelson AC, Hwang J, Kratzke RA.   +8 more
europepmc   +1 more source

GTPase KRas [PDF]

, 2020
openaire   +1 more source

Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models. [PDF]

J Clin Invest
Xu R, Wang D, Ma G, Yuan X, Chu Q, Fan S, Zhang R, Du P, Jia S, Leal TA, Ramalingam SS, Chen Z, Sun SY.   +12 more
europepmc   +1 more source

Tumor characteristics impact prognosis in deficient mismatch repair/microsatellite instability-high localized colorectal cancer-a systematic review and meta-analysis. [PDF]

JNCI Cancer Spectr
Saqi IK, Nielsen AT, Madsen MT, Gögenur I, Orhan A, Justesen TF.   +5 more
europepmc   +1 more source

Pathogenic KRAS variants disrupt structure and dynamics: Insights from integrated computational analyses. [PDF]

PLoS One
Ishaq S, Ali A, Habib O, Usmani SA, Rehman IU, Aziz A, Ali Y, Ahmad A, Ullah A.   +8 more
europepmc   +1 more source

Therapeutic strategies for KRAS G12C-mutant non-small cell lung cancer: from bench to bedside and beyond. [PDF]

Front Pharmacol
Huang R, Gong X, Du J, Xu G, Qian J, Liao G, Lin Y, Pan M, Zheng B, Yuan W, Huang Q, Chen C, Yang Z.   +12 more
europepmc   +1 more source